MedTrace Logo

Changes in Breast 3D Ultrasound Measurements Using Toremifene

NCT01417754 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-08-23

No results posted yet for this study

Summary

To investigate if there are detectable changes in volume and circulation in breasts of healthy volunteers using toremifene 20 mg in luteal phase of the menstruation cycle versus nonmedicated cycle.

Conditions

  • Circulatory; Change

Interventions

DRUG

Toremifene

20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer

Sponsors & Collaborators

  • Tampere University Hospital

    collaborator OTHER

  • Tampere University

    collaborator OTHER

  • Satakunta Central Hospital

    lead OTHER

Principal Investigators

  • Sinikka Oksa, MD · Satakunta Central Hospital

  • Johanna Mäenpää, professor · Tampere University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-11-30
Completion
2011-06-30

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01417754 on ClinicalTrials.gov